• Viralytics Ltd., of Melbourne, Australia, said it raised A$3.5 million (US$3.6 million) under its share purchase plan, accepting oversubscriptions above the A$3 million target. Funds will be used for working capital and for continuation of clinical research and development of Cavatak, an oncolytic virus candidate.